| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.45 | 0.006 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.087 | 0.007 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.007 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.008 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.009 |